US: +1 646-781-8004 | Europe:+44-203-868-8738 | APAC:+91-744-778-0008

Vaccines Market

Release date:

Jun-2021

Region:

global

Research Code:MRHC - 104377

Sku:MRHC - 104377

Vaccines Market By Indication (Influenza, Rotavirus, DTP, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccines, Live Attenuated Vaccines), and Valence (Multivalent, Monovalent Vaccines) - Forecast to 2028

  • Report ID: MRHC - 104377
  • Pages: 211
  • Jun-2021
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours
COVID-19

This report provides pre & post COVID-19 market estimates.

The vaccines market is expected reach $112.9 billion by 2028. A vaccine provides controlled exposure to a pathogen, training and strengthening the immune system to fight the disease quickly and effectively in the future. By imitating an infection, the vaccine protects against real pathogens. Governments across the globe are focused on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered the first line of defense against endemics and pandemics that may lead to healthcare emergencies. The growth of this market is majorly driven by the high prevalence of diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, the strong vaccines pipeline globally, and the emergence of the COVID-19 pandemic. Also, increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market. However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.

COVID-19 Impact Assessment

Along with the prevalence of chronic diseases, sudden outbreaks of infectious diseases, such as COVID-19, have led to a rise in mortality rates globally. With the increasing spread of COVID-19, the global population is eagerly anticipating a vaccine capable of combating the virus. As the COVID-19 pandemic has spread worldwide, governments and medical regulators are speeding up the vaccine development process. To encourage rapid progress, the FDA granted the ‘fast track’ status to several promising products. For instance, in July 2020, the Government of India speeded up the regulatory clearances needed for the Serum Institute of India’s upcoming phase III trial of the COVID-19 vaccine being developed by the University of Oxford, and it is stated to be available for mass vaccination by April 2020. In late-March 2020, Operation Warp Speed (OWS) was launched by the U.S. government. Warp Speed was commissioned to produce and deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021. In addition to Warp Speed, global efforts to build a coronavirus countermeasure spanned every continent, with China, Russia, India, Australia, Germany, and the U.K. all participating. According to the Council for Foreign Relations (CFR), governments, multilateral organizations, and private companies invested billions of dollars in developing effective vaccines by 2021. The COVAX initiative, part of the World Health Organization’s (WHO) Access to COVID-19 Tools (ACT) Accelerator, is being spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI); GAVI, the Vaccine Alliance; and WHO. The goal of the initiative is to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries. Thus, all the above collaborative efforts are expected to increase the production of coronavirus vaccines in the upcoming years, thereby propelling the growth of the vaccines market.

Increasing Government Focus on Immunization Programs

Governments across the globe are heavily focused on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered the first line of defense to avoid endemics and pandemics that may lead to healthcare emergencies. Hence, some governments are heavily focused on vaccination programs for conditions such as the Flu and Japanese Encephalitis. Many of the governments are also partnering with the private sector for enhancing vaccine research & development for diseases that pose a serious potential threat. For instance, in late-March 2020, Operation Warp Speed was launched by the U.S. government. Warp Speed was commissioned to produce and deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021. Operation Warp Speed (OWS) is a collaboration of several U.S. federal government departments, including Health and Human Services and its subagencies, Agriculture, Energy, and Veteran’s Affairs, with the private sector. OWS has selected three vaccine candidates to fund Phase 3 trials for—Moderna’s mRNA-1273, University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech's BNT162. Also, in 2019, the WHO launched its Polio Endgame Strategy 2019–2023 to immunize every child and eradicate polio. The major aims of the program include stopping all vaccine-derived poliovirus outbreaks, eliminating the risk of the emergence of polio, strengthening immunization systems by collaborating with healthcare organizations, and facilitating rapid response and immunization in case of outbreaks.

Thus, the increasing government focus on vaccine development and immunization is the major driving factor for the growth of the vaccines market.

                                               Click here to: Get Free Request Sample Copy of this report 

Long Vaccine Manufacturing Timelines to Hinder the Growth of the Vaccines Market

Due to complexities in production and associated procedures, vaccine development is considered to be a costly, complex, and time taking procedure, often lasting for about 10–15 years. During production, outcomes may vary significantly due to infinite combinations of biological materials, starting from microorganisms, equipment used, environmental conditions, and the steps followed during culturing. Also, the reagents and methods used to monitor the culture characteristics increase complexity, adding more time to the already lengthy manufacturing process.

Further, the product approval process by regulatory authorities adds to the timeline as the authorities not only analyze the quality and efficacy of the product but also the process by which the entity has been produced. Following this, vaccines enter different clinical trial phases after the manufacturer produces adequate preclinical data on safety to validate the vaccines’ activity in humans. Even after the approval, vaccine batches are tested for safety and stability as part of the process each year to ensure their adherence to the regulatory guidelines. Moreover, the longer the timeline, the higher the manufacturing cost, limiting the entry of new manufacturers into the market, thereby hindering the market’s growth.

Key Findings in the Vaccines Market Study:

The Pneumococcal Diseases Segment to Account for the Largest Market Share in 2021

The increasing prevalence of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; the development of quality vaccines such as PPSV23; and government initiatives to control the outbreaks of pneumococcal diseases are factors expected to accelerate the market’s growth.

The Subcutaneous Route of Vaccine Administration Segment to Register the Fastest Growth by 2028

The growth of this segment is driven by factors such as no requirement of trained professionals, improved adsorption of the vaccine, and the availability of multiple dosing sites. Also, the ease of self-administration by the patient supports the growth of the segment.

Multivalent Vaccines to Dominate the Market in 2021

New launches of multivalent vaccines, increasing investments by key players in the R&D of multivalent vaccines, and technological advancements in multivalent vaccine production are the major factors contributing to the large share of this segment.

Asia-Pacific to Be the Fastest-growing Regional Market

North America is estimated to command the largest share of the vaccines market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific is projected to be the fastest-growing regional market during the forecast period due to the increasing emergence of infectious diseases, the large population of patients suffering from diseases, rising public awareness regarding vaccination, and government support towards immunization.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments by leading market participants over the past four years (2017–2020). The key players profiled in the vaccines market report are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Scope of the Report:

Vaccines Market, by Indication

  • Pneumococcal Diseases
  • Influenza
  • Human Papillomavirus (HPV)
  • DTP
  • Meningococcal Disease
  • MMR
  • Rotavirus
  • Poliomyelitis (Polio)
  • Hepatitis
  • COVID-19
  • Other Indications

(Note: Other Indications Include Varicella, Herpes Zoster, Chlorella, Severe Acute Respiratory Syndrome, and Rabies)

 Vaccines Market, by Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intradermal
  • Nasal

 Vaccines Market, by Type/Antigen

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit and Conjugate Vaccines
  • Toxoid Vaccines
  • Combination Vaccines

 Vaccines Market, by Valence

  • Monovalent Vaccines
  • Polyvalent (Multivalent) Vaccines

 Vaccines Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key Questions Answered in the Report:

What is the focus of the global vaccines market study?

The vaccines market study covers the market sizes and forecasts for various vaccines used against infectious diseases. The vaccines market studied in this report includes the value analysis of various vaccine segments and subsegments at the regional and country levels.

What is the value of revenue generated from vaccines across the globe? At what rate is the demand for vaccines expected to grow for the next 5–7 years?

The vaccines market is projected to reach $112.9 billion by 2028,.

Which antigen type is estimated to hold the major share of the market?

Based on antigen type, in 2021, the subunit and conjugate vaccines segment is estimated to account for the largest share of the vaccines market due to their ability to ensure long-term immunity and their high safety and stability compared to other antigens.

Which disease indication segment is projected to gain more traction in the vaccines market?

In 2021, the pneumococcal diseases segment is estimated to account for the largest share of the vaccines market due to factors such as the increasing prevalence of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; the development of quality vaccines such as PPSV23; and initiatives by government organizations to control outbreaks of pneumococcal diseases.

What are the key factors supporting the growth of this market? What are the major opportunities for existing market players and new entrants in the global vaccines market?

The high prevalence of diseases, increasing government initiatives towards immunization, technological advancements in vaccine production, a strong vaccines pipeline globally, and the emergence of COVID-19 are factors expected to support this market’s growth. The increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market.

Who are the major players operating in the global vaccines market?

The key players operating in the vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.), among others.

Which regions/countries are expected to offer significant growth opportunities for the players operating in the vaccines market?

Emerging economies in Asia-Pacific such as China and India are projected to offer significant growth opportunities for the players in this market due to an increase in the emergence of infectious diseases, the large population of patients suffering from diseases, rising public awareness regarding the importance of vaccination, and government support towards immunization.

1.   Introduction
      1.1.    Market Definition
      1.2.    Market Ecosystem
      1.3.    Currency
      1.4.    Key Stakeholders

2.   Research Methodology
      2.1.    Research Process
      2.2.    Data Collection and Validation
                2.2.1.    Secondary Research
                2.2.2.    Primary Research
      2.3.    Market Assessment
                2.3.1.    Market Size Estimation
                             2.3.1.1.    Bottom-up Approach
                             2.3.1.2.    Top-down Approach
                             2.3.1.3.    Growth Forecast
                2.3.2.    Market Share Analysis
      2.4.    Assumptions for the Study
      2.5.    Limitations for the Study

3.   Executive Summary

4.   Market Insights

      4.1.    Market Overview
      4.2.    Market Dynamics
                4.2.1.    Drivers
                            4.2.1.1.        Strong Vaccines Pipeline
                            4.2.1.2.        Rising Prevalence of Infectious Diseases
                            4.2.1.3.        Increasing Government Focus on Immunization Programs
                            4.2.1.4.        Technological Advancements in Vaccine Administration
                            4.2.1.5.        The Impact of COVID-19
               4.2.2.    Restraints
                           4.2.2.1.        High Costs Involved in Vaccine Development
                           4.2.2.2.        Long Timelines of Vaccine Manufacturing
               4.2.3.    Opportunities
                           4.2.3.1.        Increasing Epidemic Potential
                           4.2.3.2.        Growing Focus on Therapeutic Vaccines
                           4.2.3.3.        Growth Prospects in Emerging Markets
                           4.2.3.4.        Increasing Use of Adjuvants in Vaccines
               4.2.4.    Challenges
                           4.2.4.1.        Product Recalls
                           4.2.4.2.        Inadequate Access to Vaccines

5.    Industry Analysis
      5.1.    Regulatory Analysis
      5.2.    Pipeline Analysis
      5.3.    Unmet Needs Analysis
      5.4.    Pricing Analysis, by Region

6.    Global Vaccines Market, by Indication
       6.1.    Introduction
       6.2.    Pneumococcal Diseases
       6.3.    Influenza
       6.4.    Human Papillomavirus (HPV)
       6.5.    DTP
       6.6.    Meningococcal Disease
       6.7.    MMR
       6.8.    Rotavirus
       6.9.    Poliomyelitis (Polio)      
       6.10.    Hepatitis
       6.11.    COVID-19
       6.12.    Other Indications

7.    Global Vaccines Market, by Route of Administration
       7.1.    Introduction
       7.2.    Intramuscular (IM)
       7.3.    Subcutaneous (SC)
       7.4.    Oral
       7.5.    Others

8.    Global Vaccines Market, by Type/Antigen
       8.1.    Introduction
       8.2.    Subunit and Conjugate Vaccines
       8.3.    Inactivated Vaccines
       8.4.    Live Attenuated Vaccines
       8.5.    Toxoid Vaccines
       8.6.    Combination Vaccines

9.    Global Vaccines Market, by Valence
      9.1.    Introduction
      9.2.    Multivalent Vaccines
      9.3.    Monovalent Vaccines

10.    Global Vaccines Market, by Geography
         10.1.    Introduction
         10.2.    North America
                    10.2.1.    U.S.
                    10.2.2.    Canada
         10.3.    Europe
                    10.3.1.    Germany
                    10.3.2.    U.K.
                    10.3.3.    France
                    10.3.4.    Italy
                    10.3.5.    Spain
                    10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                    10.4.1.    Japan
                    10.4.2.    China
                    10.4.3.    India
                    10.4.4.    Rest of Asia-Pacific
         10.5.    Latin America
         10.6.    Middle East & Africa

11.    Competitive Landscape
         11.1.    Introduction
         11.2.    Key Growth Strategies
         11.3.    Competitive Benchmarking
         11.4.    Market Share Analysis
                     11.4.1.    Market Share Analysis, by Company
                     11.4.2.    Market Share Analysis, by Product

12.    Company Profiles (Business Overview, Financial Overview, Product Portfolio, Pipeline Products, Strategic Developments)
         12.1.    Sanofi
         12.2.    Merck & Co., Inc.
         12.3.    GlaxoSmithKline plc.
         12.4.    Pfizer, Inc.
         12.5.    Johnson & Johnson
         12.6.    Daiichi Sankyo Co., Ltd.
         12.7.    Takeda Pharmaceutical Company Limited
         12.8.    CSL Limited
         12.9.    Emergent BioSolutions Inc.
         12.10.    AstraZeneca plc

13.    Appendix
         13.1.    Questionnaire
         13.2.    Available Customization

List of Tables

Table 1        Global Vaccines Market Drivers: Impact Analysis (2020–2027)
Table 2        Some of the Coronavirus Vaccines Under Development
Table 3        Key Government Regulatory Agencies
Table 4        Some of the Promising Vaccines in the Pipeline
Table 5        ASP of Key Vaccines, by Region (USD Per Unit)
Table 6        Global Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 7        Overview: Pneumococcal Diseases
Table 8        Pneumococcal Diseases: Vaccines in the Pipeline
Table 9        Key Companies Offering Vaccines for Pneumococcal Diseases
Table 10    Global Pneumococcal Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 11    Overview: Influenza 
Table 12    Influenza: Vaccines in the Pipeline 
Table 13    Key Companies Offering Influenza Vaccines
Table 14    Global Influenza Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 15    Overview: HPV 
Table 16    HPV Vaccine Costs (2018)
Table 17    Global Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 
2018–2027 (USD Million)
Table 18    Overview: Diphtheria, Tetanus, Pertussis Disease
Table 19    Global Supply of D&T by Product Group
Table 20    Key Companies Offering DTP Vaccines
Table 21    Global DTP Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 22    Overview: Meningococcal Disease
Table 23    Marketed Meningococcal Vaccine Combinations
Table 24    Key Companies Offering Vaccines for Meningococcal Disease
Table 25    Global Meningococcal Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 26    Overview: Measles, Mumps, and Rubella 
Table 27    Key Companies Offering MMR Vaccines
Table 28    Global MMR Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 29    Overview: Rotavirus
Table 30    Key Companies Offering Vaccines for Rotavirus
Table 31    Global Rotavirus Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 32    Overview: Poliomyelitis
Table 33    Polio Cases and Endemic Countries
Table 34    Key Companies Offering Polio Vaccines
Table 35    Global Polio Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 36    Overview: Hepatitis A
Table 37    Overview: Hepatitis B
Table 38    Key Companies Offering Hepatitis Vaccines
Table 39    Global Hepatitis Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 40    Global Other Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 41    Global Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 42    Intramuscular Sites of Vaccine Administration, by Age Group
Table 43    Vaccines for Intramuscular Administration
Table 44    Key Companies Offering Intramuscular Vaccines
Table 45    Global Intramuscular Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 46    Sites of Administration for Subcutaneous Vaccines by Age Group
Table 47    Vaccines for Subcutaneous Administration
Table 48    Key Companies Offering Subcutaneous Vaccines
Table 49    Global Subcutaneous Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 50    Key Companies Offering Oral Vaccines
Table 51    Global Oral Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 52    Global Other (Routes of Administration) Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 53    Types of Vaccines, by Antigen
Table 54    Global Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 55    Companies Offering Subunit and Conjugate Vaccines
Table 56    Global Subunit and Conjugate Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 57    Companies Offering Inactivated Vaccines
Table 58    Global Inactivated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 59    Live Attenuated COVID-19 Vaccine Candidates in Phase-III Trials
Table 60    Companies Offering Live Attenuated Vaccines
Table 61    Global Live Attenuated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 62    Toxoid Vaccines Used in the Vaccination Schedule
Table 63    Companies Offering Toxoid Vaccines
Table 64    Global Toxoid Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 65    Companies Offering Combination Vaccines
Table 66    Global Combination Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 67    Global Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 68    Multivalent Vaccines Available for Children
Table 69    Companies Offering Multivalent Vaccines
Table 70    Global Multivalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 71    Malaria, Ebola, and Dengue Vaccines in the Pipeline
Table 72    Companies Offering Monovalent Vaccines
Table 73    Global Monovalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 74    Global Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 75    North America: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 76    North America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 77    North America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 78    North America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 79    North America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 80    Influenza Burden in the U.S., 2012–2018
Table 81    Some of the Coronavirus Vaccines in Development in the U.S.
Table 82    Pfizer Inc.: Vaccines Pipeline in the U.S.
Table 83    U.S.: Macro Indicators
Table 84    U.S.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 85    U.S.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 86    U.S.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 87    U.S.: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 88    Canada: Macro Indicators
Table 89    Canada: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 90    Canada: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 91    Canada: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 92    Canada: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 93    Europe: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 94    Europe: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 95    Europe: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 96    Europe: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 97    Europe: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 98    Germany: Macro Indicators
Table 99    Germany: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 100    Germany: Vaccines Market Size, by Route of Administration, 2018-27 (USD Million)
Table 101    Germany: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 102    Germany: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 103    U.K.: Macro Indicators
Table 104    U.K.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 105    U.K.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 106    U.K.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 107    U.K.: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 108    France: Macro Indicators
Table 109    France: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 110    France: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 111    France: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 112    France: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 113    Italy: Macro Indicators
Table 114    Italy: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 115    Italy: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 116    Italy: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 117    Italy: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 118    Spain: Macro Indicators
Table 119    Spain: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 120    Spain: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 122    Spain: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 123    RoE: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 124    RoE: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 125    RoE: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 126    RoE: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 127    Asia-Pacific: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 128    Asia-Pacific: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 129    Asia-Pacific: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 130    Asia-Pacific: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 131    Asia-Pacific: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 132    Japan: Macro Indicators
Table 133    Japan: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 134    Japan: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 135    Japan: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 136    Japan: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 137    Few of the Coronavirus Vaccines in Development in China
Table 138    China: Macro Indicators
Table 139    China: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 140    China: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 141    China: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 142    China: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 143    Costs of Some of the Vaccines in India
Table 144    India: Macro Indicators
Table 145    India: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 146    India: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 147    India: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 148    India: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 149    RoAPAC: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 150    RoAPAC: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 151    RoAPAC: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 152    RoAPAC: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 153    Latin America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 154    Latin America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 155    Latin America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 156    Latin America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 157    Middle East & Africa: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 158    Middle East & Africa: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 159    Middle East & Africa: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 160    Middle East & Africa: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 161    Number of Developments by the Major Players During 2017–2020
Table 162    Vaccines Market: Competitive Benchmarking, by Product
Table 163    Vaccines Market: Competitive Benchmarking, by Geography

List of Figures

Figure 1        Research Process
Figure 2        Key Secondary Sources
Figure 3        Primary Research Techniques
Figure 4        Key Executives Interviewed
Figure 5        Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6        Market Size Estimation
Figure 7        Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 8        Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 9        Global Vaccines Market Size, by Antigen/Type, 2020–2027 (USD Million)
Figure 10    Multivalent Vaccine Segment to Dominate the Global Vaccines Market During the Forecast Period
Figure 11    Vaccines Market Overview, by Region
Figure 12    Health Products in the Pipeline: 2019
Figure 13    Vaccine Projects in the Pipeline: 2019
Figure 14    Disposable Income Per Capita in China (In USD): 2014–2019
Figure 15    Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010–2018
Figure 16    Decrease in the Number of Tuberculosis Deaths: 2012–2019
Figure 17    Therapeutic Vaccines in the Pipeline for Cancer: 2011 and 2018
Figure 18    New Cancer Cases in Asia, Latin America, and the Caribbean: 2018–2040
Figure 19    Vaccines Market Product Pipeline, by Phase (2018)
Figure 20    Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 21    Influenza Vaccines Distribution: 2016–2019
Figure 22    Forecasted Global Demand for DTWP Vaccines: 2018–2032
Figure 23    MMR Vaccines Supply: 2016–2019
Figure 24    Global Vaccination Coverage for Rotavirus: 2010–2018
Figure 25    U.S. Funding for Global Polio: 2013–2019
Figure 26    Different Routes of Vaccine Administration
Figure 27    Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 28    Global Vaccines Market Size, by Type, 2020–2027 (USD Million)
Figure 29    Global Vaccines Market Size, by Valence, 2020–2027 (USD Million)
Figure 30    Global Vaccines Market Size, by Region, 2020–2027 (USD Million)
Figure 31    North America: Snapshot
Figure 32    U.S. Funding for Global Polio: 2013–2019
Figure 33    Europe: Snapshot
Figure 34    Increase in Immunization after Mandatory Vaccination
Figure 35    Increase in the Number of Registered Influenza Cases (2015–2019)
Figure 36    Spain: Increase in the Number of Biotechnology Companies (2010–2016)
Figure 37    Asia-Pacific: Snapshot
Figure 38    India: Increasing Health Expenditure (2010–2019)
Figure 39    Cancer Incidence in the Middle East & Africa: 2018 and 2030
Figure 40    Key Growth Strategies Adopted by Leading Players, 2017–2020
Figure 41    Global Vaccines Market Share, by Key Player, 2019 (%)
Figure 42    Vaccines Market Share Analysis, by Brand (2019)
Figure 43    Sanofi: Financial Overview (2019)
Figure 44    Merck & Co., Inc.: Financial Overview (2019)
Figure 45    GlaxoSmithKline plc (GSK): Financial Overview (2019)
Figure 46    Pfizer Inc.: Financial Overview (2019)
Figure 47    Johnson & Johnson (J&J): Financial Overview (2019)
Figure 48    Daichi Sankyo Co., Ltd.: Financial Overview (2019)
Figure 49    Takeda Pharmaceutical: Financial Overview (2019)
Figure 50    CSL Limited: Financial Overview (2019)
Figure 51    Emergent Biosolutions Inc.: Financial Overview (2019)
Figure 52    AstraZeneca plc: Financial Overview (2019)

 
Name can only consist of alphabets.
Please provide your full name.
 
Please provide valid email address.
Please provide your email address.
 
Please provide your job title.
 
Please provide your company name.
 
Please provide your company name.
 
Please provide valid phone number.
Please provide your phone number.
 
Please enter minimum 10 characters.
 
Please enter Captcha.
Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

Related Research

The vaccines market is expected reach $112.9 billion by 2028. A vaccine provides controlled exposure to a pathogen, training and strengthening the immune system to fight the disease quickly and effectively in the future. By imitating an infection, the vaccine protects against real pathogens. Governments across the globe are focused on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered the first line of defense against endemics and pandemics that may lead to healthcare emergencies. The growth of this market is majorly driven by the high prevalence of diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, the strong vaccines pipeline globally, and the emergence of the COVID-19 pandemic. Also, increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market. However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.

COVID-19 Impact Assessment

Along with the prevalence of chronic diseases, sudden outbreaks of infectious diseases, such as COVID-19, have led to a rise in mortality rates globally. With the increasing spread of COVID-19, the global population is eagerly anticipating a vaccine capable of combating the virus. As the COVID-19 pandemic has spread worldwide, governments and medical regulators are speeding up the vaccine development process. To encourage rapid progress, the FDA granted the ‘fast track’ status to several promising products. For instance, in July 2020, the Government of India speeded up the regulatory clearances needed for the Serum Institute of India’s upcoming phase III trial of the COVID-19 vaccine being developed by the University of Oxford, and it is stated to be available for mass vaccination by April 2020. In late-March 2020, Operation Warp Speed (OWS) was launched by the U.S. government. Warp Speed was commissioned to produce and deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021. In addition to Warp Speed, global efforts to build a coronavirus countermeasure spanned every continent, with China, Russia, India, Australia, Germany, and the U.K. all participating. According to the Council for Foreign Relations (CFR), governments, multilateral organizations, and private companies invested billions of dollars in developing effective vaccines by 2021. The COVAX initiative, part of the World Health Organization’s (WHO) Access to COVID-19 Tools (ACT) Accelerator, is being spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI); GAVI, the Vaccine Alliance; and WHO. The goal of the initiative is to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries. Thus, all the above collaborative efforts are expected to increase the production of coronavirus vaccines in the upcoming years, thereby propelling the growth of the vaccines market.

Increasing Government Focus on Immunization Programs

Governments across the globe are heavily focused on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered the first line of defense to avoid endemics and pandemics that may lead to healthcare emergencies. Hence, some governments are heavily focused on vaccination programs for conditions such as the Flu and Japanese Encephalitis. Many of the governments are also partnering with the private sector for enhancing vaccine research & development for diseases that pose a serious potential threat. For instance, in late-March 2020, Operation Warp Speed was launched by the U.S. government. Warp Speed was commissioned to produce and deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021. Operation Warp Speed (OWS) is a collaboration of several U.S. federal government departments, including Health and Human Services and its subagencies, Agriculture, Energy, and Veteran’s Affairs, with the private sector. OWS has selected three vaccine candidates to fund Phase 3 trials for—Moderna’s mRNA-1273, University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech's BNT162. Also, in 2019, the WHO launched its Polio Endgame Strategy 2019–2023 to immunize every child and eradicate polio. The major aims of the program include stopping all vaccine-derived poliovirus outbreaks, eliminating the risk of the emergence of polio, strengthening immunization systems by collaborating with healthcare organizations, and facilitating rapid response and immunization in case of outbreaks.

Thus, the increasing government focus on vaccine development and immunization is the major driving factor for the growth of the vaccines market.

                                               Click here to: Get Free Request Sample Copy of this report 

Long Vaccine Manufacturing Timelines to Hinder the Growth of the Vaccines Market

Due to complexities in production and associated procedures, vaccine development is considered to be a costly, complex, and time taking procedure, often lasting for about 10–15 years. During production, outcomes may vary significantly due to infinite combinations of biological materials, starting from microorganisms, equipment used, environmental conditions, and the steps followed during culturing. Also, the reagents and methods used to monitor the culture characteristics increase complexity, adding more time to the already lengthy manufacturing process.

Further, the product approval process by regulatory authorities adds to the timeline as the authorities not only analyze the quality and efficacy of the product but also the process by which the entity has been produced. Following this, vaccines enter different clinical trial phases after the manufacturer produces adequate preclinical data on safety to validate the vaccines’ activity in humans. Even after the approval, vaccine batches are tested for safety and stability as part of the process each year to ensure their adherence to the regulatory guidelines. Moreover, the longer the timeline, the higher the manufacturing cost, limiting the entry of new manufacturers into the market, thereby hindering the market’s growth.

Key Findings in the Vaccines Market Study:

The Pneumococcal Diseases Segment to Account for the Largest Market Share in 2021

The increasing prevalence of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; the development of quality vaccines such as PPSV23; and government initiatives to control the outbreaks of pneumococcal diseases are factors expected to accelerate the market’s growth.

The Subcutaneous Route of Vaccine Administration Segment to Register the Fastest Growth by 2028

The growth of this segment is driven by factors such as no requirement of trained professionals, improved adsorption of the vaccine, and the availability of multiple dosing sites. Also, the ease of self-administration by the patient supports the growth of the segment.

Multivalent Vaccines to Dominate the Market in 2021

New launches of multivalent vaccines, increasing investments by key players in the R&D of multivalent vaccines, and technological advancements in multivalent vaccine production are the major factors contributing to the large share of this segment.

Asia-Pacific to Be the Fastest-growing Regional Market

North America is estimated to command the largest share of the vaccines market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific is projected to be the fastest-growing regional market during the forecast period due to the increasing emergence of infectious diseases, the large population of patients suffering from diseases, rising public awareness regarding vaccination, and government support towards immunization.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments by leading market participants over the past four years (2017–2020). The key players profiled in the vaccines market report are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Scope of the Report:

Vaccines Market, by Indication

  • Pneumococcal Diseases
  • Influenza
  • Human Papillomavirus (HPV)
  • DTP
  • Meningococcal Disease
  • MMR
  • Rotavirus
  • Poliomyelitis (Polio)
  • Hepatitis
  • COVID-19
  • Other Indications

(Note: Other Indications Include Varicella, Herpes Zoster, Chlorella, Severe Acute Respiratory Syndrome, and Rabies)

 Vaccines Market, by Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intradermal
  • Nasal

 Vaccines Market, by Type/Antigen

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit and Conjugate Vaccines
  • Toxoid Vaccines
  • Combination Vaccines

 Vaccines Market, by Valence

  • Monovalent Vaccines
  • Polyvalent (Multivalent) Vaccines

 Vaccines Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key Questions Answered in the Report:

  Request Sample

1.   Introduction
      1.1.    Market Definition
      1.2.    Market Ecosystem
      1.3.    Currency
      1.4.    Key Stakeholders

2.   Research Methodology
      2.1.    Research Process
      2.2.    Data Collection and Validation
                2.2.1.    Secondary Research
                2.2.2.    Primary Research
      2.3.    Market Assessment
                2.3.1.    Market Size Estimation
                             2.3.1.1.    Bottom-up Approach
                             2.3.1.2.    Top-down Approach
                             2.3.1.3.    Growth Forecast
                2.3.2.    Market Share Analysis
      2.4.    Assumptions for the Study
      2.5.    Limitations for the Study

3.   Executive Summary

4.   Market Insights

      4.1.    Market Overview
      4.2.    Market Dynamics
                4.2.1.    Drivers
                            4.2.1.1.        Strong Vaccines Pipeline
                            4.2.1.2.        Rising Prevalence of Infectious Diseases
                            4.2.1.3.        Increasing Government Focus on Immunization Programs
                            4.2.1.4.        Technological Advancements in Vaccine Administration
                            4.2.1.5.        The Impact of COVID-19
               4.2.2.    Restraints
                           4.2.2.1.        High Costs Involved in Vaccine Development
                           4.2.2.2.        Long Timelines of Vaccine Manufacturing
               4.2.3.    Opportunities
                           4.2.3.1.        Increasing Epidemic Potential
                           4.2.3.2.        Growing Focus on Therapeutic Vaccines
                           4.2.3.3.        Growth Prospects in Emerging Markets
                           4.2.3.4.        Increasing Use of Adjuvants in Vaccines
               4.2.4.    Challenges
                           4.2.4.1.        Product Recalls
                           4.2.4.2.        Inadequate Access to Vaccines

5.    Industry Analysis
      5.1.    Regulatory Analysis
      5.2.    Pipeline Analysis
      5.3.    Unmet Needs Analysis
      5.4.    Pricing Analysis, by Region

6.    Global Vaccines Market, by Indication
       6.1.    Introduction
       6.2.    Pneumococcal Diseases
       6.3.    Influenza
       6.4.    Human Papillomavirus (HPV)
       6.5.    DTP
       6.6.    Meningococcal Disease
       6.7.    MMR
       6.8.    Rotavirus
       6.9.    Poliomyelitis (Polio)      
       6.10.    Hepatitis
       6.11.    COVID-19
       6.12.    Other Indications

7.    Global Vaccines Market, by Route of Administration
       7.1.    Introduction
       7.2.    Intramuscular (IM)
       7.3.    Subcutaneous (SC)
       7.4.    Oral
       7.5.    Others

8.    Global Vaccines Market, by Type/Antigen
       8.1.    Introduction
       8.2.    Subunit and Conjugate Vaccines
       8.3.    Inactivated Vaccines
       8.4.    Live Attenuated Vaccines
       8.5.    Toxoid Vaccines
       8.6.    Combination Vaccines

9.    Global Vaccines Market, by Valence
      9.1.    Introduction
      9.2.    Multivalent Vaccines
      9.3.    Monovalent Vaccines

10.    Global Vaccines Market, by Geography
         10.1.    Introduction
         10.2.    North America
                    10.2.1.    U.S.
                    10.2.2.    Canada
         10.3.    Europe
                    10.3.1.    Germany
                    10.3.2.    U.K.
                    10.3.3.    France
                    10.3.4.    Italy
                    10.3.5.    Spain
                    10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                    10.4.1.    Japan
                    10.4.2.    China
                    10.4.3.    India
                    10.4.4.    Rest of Asia-Pacific
         10.5.    Latin America
         10.6.    Middle East & Africa

11.    Competitive Landscape
         11.1.    Introduction
         11.2.    Key Growth Strategies
         11.3.    Competitive Benchmarking
         11.4.    Market Share Analysis
                     11.4.1.    Market Share Analysis, by Company
                     11.4.2.    Market Share Analysis, by Product

12.    Company Profiles (Business Overview, Financial Overview, Product Portfolio, Pipeline Products, Strategic Developments)
         12.1.    Sanofi
         12.2.    Merck & Co., Inc.
         12.3.    GlaxoSmithKline plc.
         12.4.    Pfizer, Inc.
         12.5.    Johnson & Johnson
         12.6.    Daiichi Sankyo Co., Ltd.
         12.7.    Takeda Pharmaceutical Company Limited
         12.8.    CSL Limited
         12.9.    Emergent BioSolutions Inc.
         12.10.    AstraZeneca plc

13.    Appendix
         13.1.    Questionnaire
         13.2.    Available Customization

List of Tables

Table 1        Global Vaccines Market Drivers: Impact Analysis (2020–2027)
Table 2        Some of the Coronavirus Vaccines Under Development
Table 3        Key Government Regulatory Agencies
Table 4        Some of the Promising Vaccines in the Pipeline
Table 5        ASP of Key Vaccines, by Region (USD Per Unit)
Table 6        Global Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 7        Overview: Pneumococcal Diseases
Table 8        Pneumococcal Diseases: Vaccines in the Pipeline
Table 9        Key Companies Offering Vaccines for Pneumococcal Diseases
Table 10    Global Pneumococcal Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 11    Overview: Influenza 
Table 12    Influenza: Vaccines in the Pipeline 
Table 13    Key Companies Offering Influenza Vaccines
Table 14    Global Influenza Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 15    Overview: HPV 
Table 16    HPV Vaccine Costs (2018)
Table 17    Global Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 
2018–2027 (USD Million)
Table 18    Overview: Diphtheria, Tetanus, Pertussis Disease
Table 19    Global Supply of D&T by Product Group
Table 20    Key Companies Offering DTP Vaccines
Table 21    Global DTP Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 22    Overview: Meningococcal Disease
Table 23    Marketed Meningococcal Vaccine Combinations
Table 24    Key Companies Offering Vaccines for Meningococcal Disease
Table 25    Global Meningococcal Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 26    Overview: Measles, Mumps, and Rubella 
Table 27    Key Companies Offering MMR Vaccines
Table 28    Global MMR Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 29    Overview: Rotavirus
Table 30    Key Companies Offering Vaccines for Rotavirus
Table 31    Global Rotavirus Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 32    Overview: Poliomyelitis
Table 33    Polio Cases and Endemic Countries
Table 34    Key Companies Offering Polio Vaccines
Table 35    Global Polio Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 36    Overview: Hepatitis A
Table 37    Overview: Hepatitis B
Table 38    Key Companies Offering Hepatitis Vaccines
Table 39    Global Hepatitis Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 40    Global Other Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 41    Global Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 42    Intramuscular Sites of Vaccine Administration, by Age Group
Table 43    Vaccines for Intramuscular Administration
Table 44    Key Companies Offering Intramuscular Vaccines
Table 45    Global Intramuscular Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 46    Sites of Administration for Subcutaneous Vaccines by Age Group
Table 47    Vaccines for Subcutaneous Administration
Table 48    Key Companies Offering Subcutaneous Vaccines
Table 49    Global Subcutaneous Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 50    Key Companies Offering Oral Vaccines
Table 51    Global Oral Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 52    Global Other (Routes of Administration) Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 53    Types of Vaccines, by Antigen
Table 54    Global Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 55    Companies Offering Subunit and Conjugate Vaccines
Table 56    Global Subunit and Conjugate Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 57    Companies Offering Inactivated Vaccines
Table 58    Global Inactivated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 59    Live Attenuated COVID-19 Vaccine Candidates in Phase-III Trials
Table 60    Companies Offering Live Attenuated Vaccines
Table 61    Global Live Attenuated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 62    Toxoid Vaccines Used in the Vaccination Schedule
Table 63    Companies Offering Toxoid Vaccines
Table 64    Global Toxoid Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 65    Companies Offering Combination Vaccines
Table 66    Global Combination Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 67    Global Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 68    Multivalent Vaccines Available for Children
Table 69    Companies Offering Multivalent Vaccines
Table 70    Global Multivalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 71    Malaria, Ebola, and Dengue Vaccines in the Pipeline
Table 72    Companies Offering Monovalent Vaccines
Table 73    Global Monovalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 74    Global Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 75    North America: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 76    North America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 77    North America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 78    North America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 79    North America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 80    Influenza Burden in the U.S., 2012–2018
Table 81    Some of the Coronavirus Vaccines in Development in the U.S.
Table 82    Pfizer Inc.: Vaccines Pipeline in the U.S.
Table 83    U.S.: Macro Indicators
Table 84    U.S.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 85    U.S.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 86    U.S.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 87    U.S.: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 88    Canada: Macro Indicators
Table 89    Canada: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 90    Canada: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 91    Canada: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 92    Canada: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 93    Europe: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 94    Europe: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 95    Europe: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 96    Europe: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 97    Europe: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 98    Germany: Macro Indicators
Table 99    Germany: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 100    Germany: Vaccines Market Size, by Route of Administration, 2018-27 (USD Million)
Table 101    Germany: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 102    Germany: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 103    U.K.: Macro Indicators
Table 104    U.K.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 105    U.K.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 106    U.K.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 107    U.K.: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 108    France: Macro Indicators
Table 109    France: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 110    France: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 111    France: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 112    France: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 113    Italy: Macro Indicators
Table 114    Italy: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 115    Italy: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 116    Italy: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 117    Italy: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 118    Spain: Macro Indicators
Table 119    Spain: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 120    Spain: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 122    Spain: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 123    RoE: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 124    RoE: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 125    RoE: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 126    RoE: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 127    Asia-Pacific: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 128    Asia-Pacific: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 129    Asia-Pacific: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 130    Asia-Pacific: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 131    Asia-Pacific: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 132    Japan: Macro Indicators
Table 133    Japan: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 134    Japan: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 135    Japan: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 136    Japan: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 137    Few of the Coronavirus Vaccines in Development in China
Table 138    China: Macro Indicators
Table 139    China: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 140    China: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 141    China: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 142    China: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 143    Costs of Some of the Vaccines in India
Table 144    India: Macro Indicators
Table 145    India: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 146    India: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 147    India: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 148    India: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 149    RoAPAC: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 150    RoAPAC: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 151    RoAPAC: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 152    RoAPAC: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 153    Latin America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 154    Latin America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 155    Latin America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 156    Latin America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 157    Middle East & Africa: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 158    Middle East & Africa: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 159    Middle East & Africa: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 160    Middle East & Africa: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 161    Number of Developments by the Major Players During 2017–2020
Table 162    Vaccines Market: Competitive Benchmarking, by Product
Table 163    Vaccines Market: Competitive Benchmarking, by Geography

List of Figures

Figure 1        Research Process
Figure 2        Key Secondary Sources
Figure 3        Primary Research Techniques
Figure 4        Key Executives Interviewed
Figure 5        Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6        Market Size Estimation
Figure 7        Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 8        Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 9        Global Vaccines Market Size, by Antigen/Type, 2020–2027 (USD Million)
Figure 10    Multivalent Vaccine Segment to Dominate the Global Vaccines Market During the Forecast Period
Figure 11    Vaccines Market Overview, by Region
Figure 12    Health Products in the Pipeline: 2019
Figure 13    Vaccine Projects in the Pipeline: 2019
Figure 14    Disposable Income Per Capita in China (In USD): 2014–2019
Figure 15    Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010–2018
Figure 16    Decrease in the Number of Tuberculosis Deaths: 2012–2019
Figure 17    Therapeutic Vaccines in the Pipeline for Cancer: 2011 and 2018
Figure 18    New Cancer Cases in Asia, Latin America, and the Caribbean: 2018–2040
Figure 19    Vaccines Market Product Pipeline, by Phase (2018)
Figure 20    Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 21    Influenza Vaccines Distribution: 2016–2019
Figure 22    Forecasted Global Demand for DTWP Vaccines: 2018–2032
Figure 23    MMR Vaccines Supply: 2016–2019
Figure 24    Global Vaccination Coverage for Rotavirus: 2010–2018
Figure 25    U.S. Funding for Global Polio: 2013–2019
Figure 26    Different Routes of Vaccine Administration
Figure 27    Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 28    Global Vaccines Market Size, by Type, 2020–2027 (USD Million)
Figure 29    Global Vaccines Market Size, by Valence, 2020–2027 (USD Million)
Figure 30    Global Vaccines Market Size, by Region, 2020–2027 (USD Million)
Figure 31    North America: Snapshot
Figure 32    U.S. Funding for Global Polio: 2013–2019
Figure 33    Europe: Snapshot
Figure 34    Increase in Immunization after Mandatory Vaccination
Figure 35    Increase in the Number of Registered Influenza Cases (2015–2019)
Figure 36    Spain: Increase in the Number of Biotechnology Companies (2010–2016)
Figure 37    Asia-Pacific: Snapshot
Figure 38    India: Increasing Health Expenditure (2010–2019)
Figure 39    Cancer Incidence in the Middle East & Africa: 2018 and 2030
Figure 40    Key Growth Strategies Adopted by Leading Players, 2017–2020
Figure 41    Global Vaccines Market Share, by Key Player, 2019 (%)
Figure 42    Vaccines Market Share Analysis, by Brand (2019)
Figure 43    Sanofi: Financial Overview (2019)
Figure 44    Merck & Co., Inc.: Financial Overview (2019)
Figure 45    GlaxoSmithKline plc (GSK): Financial Overview (2019)
Figure 46    Pfizer Inc.: Financial Overview (2019)
Figure 47    Johnson & Johnson (J&J): Financial Overview (2019)
Figure 48    Daichi Sankyo Co., Ltd.: Financial Overview (2019)
Figure 49    Takeda Pharmaceutical: Financial Overview (2019)
Figure 50    CSL Limited: Financial Overview (2019)
Figure 51    Emergent Biosolutions Inc.: Financial Overview (2019)
Figure 52    AstraZeneca plc: Financial Overview (2019)

  Request Sample

1.   Introduction
      1.1.    Market Definition
      1.2.    Market Ecosystem
      1.3.    Currency
      1.4.    Key Stakeholders

2.   Research Methodology
      2.1.    Research Process
      2.2.    Data Collection and Validation
                2.2.1.    Secondary Research
                2.2.2.    Primary Research
      2.3.    Market Assessment
                2.3.1.    Market Size Estimation
                             2.3.1.1.    Bottom-up Approach
                             2.3.1.2.    Top-down Approach
                             2.3.1.3.    Growth Forecast
                2.3.2.    Market Share Analysis
      2.4.    Assumptions for the Study
      2.5.    Limitations for the Study

3.   Executive Summary

4.   Market Insights

      4.1.    Market Overview
      4.2.    Market Dynamics
                4.2.1.    Drivers
                            4.2.1.1.        Strong Vaccines Pipeline
                            4.2.1.2.        Rising Prevalence of Infectious Diseases
                            4.2.1.3.        Increasing Government Focus on Immunization Programs
                            4.2.1.4.        Technological Advancements in Vaccine Administration
                            4.2.1.5.        The Impact of COVID-19
               4.2.2.    Restraints
                           4.2.2.1.        High Costs Involved in Vaccine Development
                           4.2.2.2.        Long Timelines of Vaccine Manufacturing
               4.2.3.    Opportunities
                           4.2.3.1.        Increasing Epidemic Potential
                           4.2.3.2.        Growing Focus on Therapeutic Vaccines
                           4.2.3.3.        Growth Prospects in Emerging Markets
                           4.2.3.4.        Increasing Use of Adjuvants in Vaccines
               4.2.4.    Challenges
                           4.2.4.1.        Product Recalls
                           4.2.4.2.        Inadequate Access to Vaccines

5.    Industry Analysis
      5.1.    Regulatory Analysis
      5.2.    Pipeline Analysis
      5.3.    Unmet Needs Analysis
      5.4.    Pricing Analysis, by Region

6.    Global Vaccines Market, by Indication
       6.1.    Introduction
       6.2.    Pneumococcal Diseases
       6.3.    Influenza
       6.4.    Human Papillomavirus (HPV)
       6.5.    DTP
       6.6.    Meningococcal Disease
       6.7.    MMR
       6.8.    Rotavirus
       6.9.    Poliomyelitis (Polio)      
       6.10.    Hepatitis
       6.11.    COVID-19
       6.12.    Other Indications

7.    Global Vaccines Market, by Route of Administration
       7.1.    Introduction
       7.2.    Intramuscular (IM)
       7.3.    Subcutaneous (SC)
       7.4.    Oral
       7.5.    Others

8.    Global Vaccines Market, by Type/Antigen
       8.1.    Introduction
       8.2.    Subunit and Conjugate Vaccines
       8.3.    Inactivated Vaccines
       8.4.    Live Attenuated Vaccines
       8.5.    Toxoid Vaccines
       8.6.    Combination Vaccines

9.    Global Vaccines Market, by Valence
      9.1.    Introduction
      9.2.    Multivalent Vaccines
      9.3.    Monovalent Vaccines

10.    Global Vaccines Market, by Geography
         10.1.    Introduction
         10.2.    North America
                    10.2.1.    U.S.
                    10.2.2.    Canada
         10.3.    Europe
                    10.3.1.    Germany
                    10.3.2.    U.K.
                    10.3.3.    France
                    10.3.4.    Italy
                    10.3.5.    Spain
                    10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                    10.4.1.    Japan
                    10.4.2.    China
                    10.4.3.    India
                    10.4.4.    Rest of Asia-Pacific
         10.5.    Latin America
         10.6.    Middle East & Africa

11.    Competitive Landscape
         11.1.    Introduction
         11.2.    Key Growth Strategies
         11.3.    Competitive Benchmarking
         11.4.    Market Share Analysis
                     11.4.1.    Market Share Analysis, by Company
                     11.4.2.    Market Share Analysis, by Product

12.    Company Profiles (Business Overview, Financial Overview, Product Portfolio, Pipeline Products, Strategic Developments)
         12.1.    Sanofi
         12.2.    Merck & Co., Inc.
         12.3.    GlaxoSmithKline plc.
         12.4.    Pfizer, Inc.
         12.5.    Johnson & Johnson
         12.6.    Daiichi Sankyo Co., Ltd.
         12.7.    Takeda Pharmaceutical Company Limited
         12.8.    CSL Limited
         12.9.    Emergent BioSolutions Inc.
         12.10.    AstraZeneca plc

13.    Appendix
         13.1.    Questionnaire
         13.2.    Available Customization

List of Tables

Table 1        Global Vaccines Market Drivers: Impact Analysis (2020–2027)
Table 2        Some of the Coronavirus Vaccines Under Development
Table 3        Key Government Regulatory Agencies
Table 4        Some of the Promising Vaccines in the Pipeline
Table 5        ASP of Key Vaccines, by Region (USD Per Unit)
Table 6        Global Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 7        Overview: Pneumococcal Diseases
Table 8        Pneumococcal Diseases: Vaccines in the Pipeline
Table 9        Key Companies Offering Vaccines for Pneumococcal Diseases
Table 10    Global Pneumococcal Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 11    Overview: Influenza 
Table 12    Influenza: Vaccines in the Pipeline 
Table 13    Key Companies Offering Influenza Vaccines
Table 14    Global Influenza Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 15    Overview: HPV 
Table 16    HPV Vaccine Costs (2018)
Table 17    Global Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 
2018–2027 (USD Million)
Table 18    Overview: Diphtheria, Tetanus, Pertussis Disease
Table 19    Global Supply of D&T by Product Group
Table 20    Key Companies Offering DTP Vaccines
Table 21    Global DTP Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 22    Overview: Meningococcal Disease
Table 23    Marketed Meningococcal Vaccine Combinations
Table 24    Key Companies Offering Vaccines for Meningococcal Disease
Table 25    Global Meningococcal Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 26    Overview: Measles, Mumps, and Rubella 
Table 27    Key Companies Offering MMR Vaccines
Table 28    Global MMR Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 29    Overview: Rotavirus
Table 30    Key Companies Offering Vaccines for Rotavirus
Table 31    Global Rotavirus Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 32    Overview: Poliomyelitis
Table 33    Polio Cases and Endemic Countries
Table 34    Key Companies Offering Polio Vaccines
Table 35    Global Polio Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 36    Overview: Hepatitis A
Table 37    Overview: Hepatitis B
Table 38    Key Companies Offering Hepatitis Vaccines
Table 39    Global Hepatitis Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 40    Global Other Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 41    Global Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 42    Intramuscular Sites of Vaccine Administration, by Age Group
Table 43    Vaccines for Intramuscular Administration
Table 44    Key Companies Offering Intramuscular Vaccines
Table 45    Global Intramuscular Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 46    Sites of Administration for Subcutaneous Vaccines by Age Group
Table 47    Vaccines for Subcutaneous Administration
Table 48    Key Companies Offering Subcutaneous Vaccines
Table 49    Global Subcutaneous Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 50    Key Companies Offering Oral Vaccines
Table 51    Global Oral Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 52    Global Other (Routes of Administration) Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 53    Types of Vaccines, by Antigen
Table 54    Global Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 55    Companies Offering Subunit and Conjugate Vaccines
Table 56    Global Subunit and Conjugate Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 57    Companies Offering Inactivated Vaccines
Table 58    Global Inactivated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 59    Live Attenuated COVID-19 Vaccine Candidates in Phase-III Trials
Table 60    Companies Offering Live Attenuated Vaccines
Table 61    Global Live Attenuated Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 62    Toxoid Vaccines Used in the Vaccination Schedule
Table 63    Companies Offering Toxoid Vaccines
Table 64    Global Toxoid Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 65    Companies Offering Combination Vaccines
Table 66    Global Combination Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 67    Global Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 68    Multivalent Vaccines Available for Children
Table 69    Companies Offering Multivalent Vaccines
Table 70    Global Multivalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 71    Malaria, Ebola, and Dengue Vaccines in the Pipeline
Table 72    Companies Offering Monovalent Vaccines
Table 73    Global Monovalent Vaccines Market Size, by Region/Country, 2018–2027 (USD Million)
Table 74    Global Vaccines Market Size, by Country/Region, 2018–2027 (USD Million)
Table 75    North America: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 76    North America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 77    North America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 78    North America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 79    North America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 80    Influenza Burden in the U.S., 2012–2018
Table 81    Some of the Coronavirus Vaccines in Development in the U.S.
Table 82    Pfizer Inc.: Vaccines Pipeline in the U.S.
Table 83    U.S.: Macro Indicators
Table 84    U.S.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 85    U.S.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 86    U.S.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 87    U.S.: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 88    Canada: Macro Indicators
Table 89    Canada: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 90    Canada: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 91    Canada: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 92    Canada: Vaccines Market Size, by Valence, 2017–2027 (USD Million)
Table 93    Europe: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 94    Europe: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 95    Europe: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 96    Europe: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 97    Europe: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 98    Germany: Macro Indicators
Table 99    Germany: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 100    Germany: Vaccines Market Size, by Route of Administration, 2018-27 (USD Million)
Table 101    Germany: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 102    Germany: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 103    U.K.: Macro Indicators
Table 104    U.K.: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 105    U.K.: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 106    U.K.: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 107    U.K.: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 108    France: Macro Indicators
Table 109    France: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 110    France: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 111    France: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 112    France: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 113    Italy: Macro Indicators
Table 114    Italy: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 115    Italy: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 116    Italy: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 117    Italy: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 118    Spain: Macro Indicators
Table 119    Spain: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 120    Spain: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 122    Spain: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 123    RoE: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 124    RoE: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 125    RoE: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 126    RoE: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 127    Asia-Pacific: Vaccines Market Size, by Country, 2018–2027 (USD Million)
Table 128    Asia-Pacific: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 129    Asia-Pacific: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 130    Asia-Pacific: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 131    Asia-Pacific: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 132    Japan: Macro Indicators
Table 133    Japan: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 134    Japan: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 135    Japan: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 136    Japan: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 137    Few of the Coronavirus Vaccines in Development in China
Table 138    China: Macro Indicators
Table 139    China: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 140    China: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 141    China: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 142    China: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 143    Costs of Some of the Vaccines in India
Table 144    India: Macro Indicators
Table 145    India: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 146    India: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 147    India: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 148    India: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 149    RoAPAC: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 150    RoAPAC: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 151    RoAPAC: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 152    RoAPAC: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 153    Latin America: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 154    Latin America: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 155    Latin America: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 156    Latin America: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 157    Middle East & Africa: Vaccines Market Size, by Indication, 2018–2027 (USD Million)
Table 158    Middle East & Africa: Vaccines Market Size, by Route of Administration, 2018–2027 (USD Million)
Table 159    Middle East & Africa: Vaccines Market Size, by Type, 2018–2027 (USD Million)
Table 160    Middle East & Africa: Vaccines Market Size, by Valence, 2018–2027 (USD Million)
Table 161    Number of Developments by the Major Players During 2017–2020
Table 162    Vaccines Market: Competitive Benchmarking, by Product
Table 163    Vaccines Market: Competitive Benchmarking, by Geography

List of Figures

Figure 1        Research Process
Figure 2        Key Secondary Sources
Figure 3        Primary Research Techniques
Figure 4        Key Executives Interviewed
Figure 5        Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6        Market Size Estimation
Figure 7        Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 8        Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 9        Global Vaccines Market Size, by Antigen/Type, 2020–2027 (USD Million)
Figure 10    Multivalent Vaccine Segment to Dominate the Global Vaccines Market During the Forecast Period
Figure 11    Vaccines Market Overview, by Region
Figure 12    Health Products in the Pipeline: 2019
Figure 13    Vaccine Projects in the Pipeline: 2019
Figure 14    Disposable Income Per Capita in China (In USD): 2014–2019
Figure 15    Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010–2018
Figure 16    Decrease in the Number of Tuberculosis Deaths: 2012–2019
Figure 17    Therapeutic Vaccines in the Pipeline for Cancer: 2011 and 2018
Figure 18    New Cancer Cases in Asia, Latin America, and the Caribbean: 2018–2040
Figure 19    Vaccines Market Product Pipeline, by Phase (2018)
Figure 20    Global Vaccines Market Size, by Indication, 2020–2027 (USD Million)
Figure 21    Influenza Vaccines Distribution: 2016–2019
Figure 22    Forecasted Global Demand for DTWP Vaccines: 2018–2032
Figure 23    MMR Vaccines Supply: 2016–2019
Figure 24    Global Vaccination Coverage for Rotavirus: 2010–2018
Figure 25    U.S. Funding for Global Polio: 2013–2019
Figure 26    Different Routes of Vaccine Administration
Figure 27    Global Vaccines Market Size, by Route of Administration, 2020–2027 (USD Million)
Figure 28    Global Vaccines Market Size, by Type, 2020–2027 (USD Million)
Figure 29    Global Vaccines Market Size, by Valence, 2020–2027 (USD Million)
Figure 30    Global Vaccines Market Size, by Region, 2020–2027 (USD Million)
Figure 31    North America: Snapshot
Figure 32    U.S. Funding for Global Polio: 2013–2019
Figure 33    Europe: Snapshot
Figure 34    Increase in Immunization after Mandatory Vaccination
Figure 35    Increase in the Number of Registered Influenza Cases (2015–2019)
Figure 36    Spain: Increase in the Number of Biotechnology Companies (2010–2016)
Figure 37    Asia-Pacific: Snapshot
Figure 38    India: Increasing Health Expenditure (2010–2019)
Figure 39    Cancer Incidence in the Middle East & Africa: 2018 and 2030
Figure 40    Key Growth Strategies Adopted by Leading Players, 2017–2020
Figure 41    Global Vaccines Market Share, by Key Player, 2019 (%)
Figure 42    Vaccines Market Share Analysis, by Brand (2019)
Figure 43    Sanofi: Financial Overview (2019)
Figure 44    Merck & Co., Inc.: Financial Overview (2019)
Figure 45    GlaxoSmithKline plc (GSK): Financial Overview (2019)
Figure 46    Pfizer Inc.: Financial Overview (2019)
Figure 47    Johnson & Johnson (J&J): Financial Overview (2019)
Figure 48    Daichi Sankyo Co., Ltd.: Financial Overview (2019)
Figure 49    Takeda Pharmaceutical: Financial Overview (2019)
Figure 50    CSL Limited: Financial Overview (2019)
Figure 51    Emergent Biosolutions Inc.: Financial Overview (2019)
Figure 52    AstraZeneca plc: Financial Overview (2019)

  Request Sample
Related Research